mirtazapine has been researched along with Hyperemesis Gravidarum in 8 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Hyperemesis Gravidarum: Intractable VOMITING that develops in early PREGNANCY and persists. This can lead to DEHYDRATION and WEIGHT LOSS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " One hundred and eighty pregnant women referred to secondary care for hyperemesis gravidarum will be randomly allocated to 14-day treatment with either mirtazapine, ondansetron or placebo." | 9.34 | Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial. ( Andersen, JT; Futtrup, TB; Jensen, AK; Løkkegaard, ECL; Ostenfeld, A; Pedersen, LH; Petersen, TS; Westergaard, HB, 2020) |
| "Here we present the case of a 30-year-old woman with type I diabetes mellitus, preeclampsia and treatment resistant persistent hyperemesis gravidarum in her 25th week of gestation who was successfully treated with the antidepressant mirtazapine (Remergil)." | 7.74 | Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine. ( Gembruch, U; Heep, A; Rohde, A; Schwarzer, V, 2008) |
| "Mirtazapine seems to be an effective treatment modality in patients with severe hyperemesis gravidarum who do not respond to conventional anti-emesis treatment regimens." | 7.73 | Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. ( Dogan, E; Gol, M; Guclu, S; Saygili, U, 2005) |
| " When the patient asked for termination of the pregnancy because of the unbearable symptoms, treatment with intravenous mirtazapine (Remergil) was started." | 7.72 | Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. ( Dembinski, J; Dorn, C; Rohde, A, 2003) |
| " One hundred and eighty pregnant women referred to secondary care for hyperemesis gravidarum will be randomly allocated to 14-day treatment with either mirtazapine, ondansetron or placebo." | 5.34 | Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial. ( Andersen, JT; Futtrup, TB; Jensen, AK; Løkkegaard, ECL; Ostenfeld, A; Pedersen, LH; Petersen, TS; Westergaard, HB, 2020) |
| "Here we present the case of a 30-year-old woman with type I diabetes mellitus, preeclampsia and treatment resistant persistent hyperemesis gravidarum in her 25th week of gestation who was successfully treated with the antidepressant mirtazapine (Remergil)." | 3.74 | Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine. ( Gembruch, U; Heep, A; Rohde, A; Schwarzer, V, 2008) |
| "Mirtazapine seems to be an effective treatment modality in patients with severe hyperemesis gravidarum who do not respond to conventional anti-emesis treatment regimens." | 3.73 | Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. ( Dogan, E; Gol, M; Guclu, S; Saygili, U, 2005) |
| " When the patient asked for termination of the pregnancy because of the unbearable symptoms, treatment with intravenous mirtazapine (Remergil) was started." | 3.72 | Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. ( Dembinski, J; Dorn, C; Rohde, A, 2003) |
| "Hyperemesis gravidarum is a diagnosis reserved for refractory cases of NVP and therefore by definition poses treatment challenges." | 2.66 | Management Considerations for Recalcitrant Hyperemesis. ( Dotters-Katz, S; Kuller, JA; Post, A; Spinosa, D, 2020) |
| "Hyperemesis gravidarum is not uncommon." | 1.46 | Intractable hyperemesis gravidarum in a patient with type 1 diabetes. ( Arshad, MF; Bekhit, M; Javed, N, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spinosa, D | 1 |
| Post, A | 1 |
| Kuller, JA | 1 |
| Dotters-Katz, S | 1 |
| Ostenfeld, A | 1 |
| Petersen, TS | 1 |
| Futtrup, TB | 1 |
| Andersen, JT | 1 |
| Jensen, AK | 1 |
| Westergaard, HB | 1 |
| Pedersen, LH | 1 |
| Løkkegaard, ECL | 1 |
| Arshad, MF | 1 |
| Javed, N | 1 |
| Bekhit, M | 1 |
| Abramowitz, A | 1 |
| Miller, ES | 1 |
| Wisner, KL | 1 |
| Lieb, M | 1 |
| Palm, U | 1 |
| Jacoby, D | 1 |
| Baghai, TC | 1 |
| Severus, E | 1 |
| Rohde, A | 2 |
| Dembinski, J | 1 |
| Dorn, C | 1 |
| Guclu, S | 1 |
| Gol, M | 1 |
| Dogan, E | 1 |
| Saygili, U | 1 |
| Schwarzer, V | 1 |
| Heep, A | 1 |
| Gembruch, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Validating the Effect of Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum: A Double-Blind Randomised Placebo-Controlled Multicentre Trial[NCT03785691] | Phase 2 | 58 participants (Actual) | Interventional | 2019-03-01 | Terminated (stopped due to Recruiting difficulties) | ||
| Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)[NCT05452174] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2022-06-13 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mirtazapine and Hyperemesis Gravidarum
| Article | Year |
|---|---|
Management Considerations for Recalcitrant Hyperemesis.
Topics: Adrenal Cortex Hormones; Diazepam; Disease Management; Enteral Nutrition; Female; Humans; Hyperemesi | 2020 |
Treatment options for hyperemesis gravidarum.
Topics: Adrenergic alpha-Antagonists; Adult; Antiemetics; Dopamine Agonists; Female; Humans; Hyperemesis Gra | 2017 |
1 trial available for mirtazapine and Hyperemesis Gravidarum
| Article | Year |
|---|---|
Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Mirtazapine; Multicenter Studies as Topic; Onda | 2020 |
5 other studies available for mirtazapine and Hyperemesis Gravidarum
| Article | Year |
|---|---|
Intractable hyperemesis gravidarum in a patient with type 1 diabetes.
Topics: Antiemetics; Cesarean Section; Diabetes Mellitus, Type 1; Female; Gestational Age; Humans; Hyperemes | 2017 |
[Mirtazapine and hyperemesis gravidarum].
Topics: Adult; Antidepressive Agents, Tricyclic; Female; Humans; Hyperemesis Gravidarum; Mianserin; Mirtazap | 2012 |
Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy.
Topics: Abortion, Induced; Adult; Antidepressive Agents, Tricyclic; Cesarean Section; Female; Humans; Hypere | 2003 |
Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature.
Topics: Adult; Antiemetics; Female; Humans; Hyperemesis Gravidarum; Infant, Newborn; Mianserin; Mirtazapine; | 2005 |
Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Diabetes Mellitus, Type 1; Drug Resistance; Female; Humans; | 2008 |